The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes in patients (pts) younger than 50 years old (yo) with treatment-naïve blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with tagraxofusp (TAG): Subanalysis of a phase 1/2 trial.
 
Anthony Stein
Honoraria - Amgen; Debiopharm Group; Syndex Bio
Consulting or Advisory Role - Debiopharm Group; Sanofi and Daiichi Sankyo; Syndex Bio
Speakers' Bureau - Amgen
 
Andrew Lane
Stock and Other Ownership Interests - Medzown
Consulting or Advisory Role - Cimeio Therapeutics; IDRx; Jnana Therapeutics; ProteinQure; Qiagen; Stelexis Therapeutics
Research Funding - Abbvie (Inst); Stemline Therapeutics (Inst)
Other Relationship - Stemline Therapeutics
 
Kendra Sweet
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Jazz Pharmaceuticals; Nkarta; Novartis
Research Funding - Incyte (Inst); Jazz Pharmaceuticals (Inst)
Expert Testimony - Nelson Mullins
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Jazz Pharmaceuticals
Other Relationship - Karyopharm Therapeutics
 
Sumithira Vasu
Research Funding - Sanofi (Inst)
Other Relationship - Alexion Pharmaceuticals
 
Alessandra Tosolini
Employment - GlaxoSmithKline; Menarini Group
Stock and Other Ownership Interests - GlaxoSmithKline
Patents, Royalties, Other Intellectual Property - GlaxoSmithKline
 
John Katsetos
Employment - Abbvie; Menarini Group
Stock and Other Ownership Interests - Abbvie
 
Marina Konopleva
Leadership - Immune Oncology
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; F. Hoffmann LaRoche; Genentech; Gilead Sciences; Janssen; Legend Biotech; MEI Pharma; Redona Therapeutics; Sanofi Aventis GmbH; Sellas Life Sciences; Stemline Therapeutics; Vincerx Pharma
Research Funding - Abbvie (Inst); Allogene Therapeutics (Inst); AstraZeneca (Inst); Cellectis (Inst); Genentech (Inst); Gilead Sciences (Inst); ImmunoGen (Inst); Janssen (Inst); MEI Pharma (Inst); Pfizer (Inst); Precision BioSciences (Inst); Rafael Pharmaceuticals (Inst); Sanofi Aventis GmbH (Inst); Stemline Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Reata Pharmaceuticals
Other Relationship - Abbvie; Auxenion GmbH; BAKX Therapeutics; Dark Blue Therapeutics; F. Hoffmann LaRoche; Genentech; Gilead Sciences; Stemline Therapeutics; Vincerx Pharma
 
Naveen Pemmaraju
Employment - MD Anderson Cancer Center
Leadership - ASCO; ASH
Consulting or Advisory Role - Abbvie; Aplastic Anemia and MDS International Foundation; Aptitude Health; Astellas Pharma; Blueprint Medicines; Bristol Myers Squibb; CancerNet; CareDx; Celgene; Cimeio Therapeutics; Clearview Healthcare Partners; CTI BioPharma Corp; Curio Science; Dava Oncology; EUSA Pharma; Harborside Press; Imedex; Immunogen; Intellisphere; Intellisphere; Magdalen Medical Publishing; Medscape; Menarini Group; Neopharm; Novartis; OncLive; Pacylex; Patient Power; Peerview; Pharmaessentia; Physicans' Education Resource
Research Funding - US DOD (Inst)
Other Relationship - Karger Publishers
(OPTIONAL) Uncompensated Relationships - Dan's House of Hope; Oncology Times